MIRM vs SVRA
MIRM: Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic liver disease and viral hepatitis. SVRA: Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
Side-by-side fundamentals
| Metric | MIRM | SVRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $114.48 | $5.65 | |
| Market cap as of 2026-07-23 | $7.0B | $1.2B | |
| PEG as of 2026-07-23 | -0.01 | -0.81 | SVRA lower |
| Net margin as of 2026-07-23 | -140.2% | -4253.9% | MIRM higher |
| Gross margin as of 2026-07-23 | +81.4% | +100.0% | SVRA higher |
| Operating margin as of 2026-07-23 | -139.8% | -4150.0% | MIRM higher |
| ROE as of 2026-07-23 | -289.3% | -87.2% | SVRA higher |
| ROA as of 2026-07-23 | -98.5% | -66.4% | SVRA higher |
| Debt / equity as of 2026-07-23 | 1.28 | 0.17 | SVRA lower |
| Revenue growth (YoY) as of 2026-07-23 | +50.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +89.1% | n/a | |
| Beta as of 2026-07-23 | 0.51 | 0.25 | |
| 1-year return as of 2026-07-22 close | +119.4% | +134.4% | SVRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.